Company Overview
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Why Investors Should Care
Revenue has grown at a 133.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $638.50M (+65.5% YoY); net profit $-183.17M.
- Trailing 12 Months Year-on-year growth — revenue +57.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 133.7%, profit CAGR 0.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 133.68% |
| 1 Year: | 57.40% |
Compounded Profit Growth
| 5 Years: | 0.71% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +109.44% |
| 6 Months: | +38.89% |
| 3 Months: | +31.92% |
| 1 Month: | -7.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 133.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AXSM Axsome Therapeutics, Inc. R2K | 235.26 | -63.07 | $12.11B | 0.00% | -54.42% | - | 133.68% | 0.71% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.82M | 16.85M | 94.58M | 46.70M | 57.79M | 75.00M | 87.17M | 104.76M | 121.46M | 150.04M | 170.99M | 196.00M | 191.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.79M | 13.45M | 11.91M | 12.33M | 14.72M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.67M | 136.59M | 159.08M | 183.67M | 176.48M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 167.14M | 181.41M | 192.00M | 219.69M | 239.25M |
| Operating Income | 2.08M | 2.02M | 3.15M | 5.88M | 6.83M | 7.21M | 7.63M | 7.67M | 6.75M | 6.30M | 6.44M | -7.16M | -7.99M | -8.24M | 9.45M | -10.42M | -13.45M | -18.95M | - | -32.49M | -17.78M | -21.13M | - | -27.84M | -30.85M | -33.41M | -38.29M | -39.18M | -42.41M | -6.37M | -65.06M | -62.12M | -67.28M | -78.05M | -62.62M | -55.47M | -44.82M | -32.92M | -36.02M | -62.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.85M | -44.85M | -43.70M | -24.68M | -60.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.43M | 1.83M | 1.12M | 1.17M | 1.19M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59.41M | -48.93M | -47.23M | -28.13M | -64.54M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -960.00K | 0 | 430.00K | 0 |
| Net Income | -2.13M | -4.58M | -3.36M | -5.87M | -6.81M | -7.19M | -7.33M | -8.00M | -7.08M | -6.43M | -7.43M | -4.81M | -8.28M | -8.28M | -9.60M | -10.64M | -13.76M | -19.14M | -24.81M | -32.48M | -18.33M | -22.92M | -29.16M | -29.26M | -32.28M | -34.88M | -39.63M | -41.44M | -44.82M | -11.22M | -67.17M | -62.20M | -68.36M | -79.34M | -64.60M | -59.41M | -47.97M | -47.23M | -28.56M | -64.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.86 | -0.93 | -1.06 | -1.06 | -1.07 | -0.26 | -1.54 | -1.32 | -1.44 | -1.67 | -1.34 | -1.22 | -0.97 | -0.94 | -0.56 | -1.26 |
| R&D Expense | 1.63M | 1.52M | - | 4.53M | 5.30M | 5.57M | - | 5.99M | 5.01M | 4.47M | - | 4.75M | 5.55M | 6.04M | - | 7.60M | 11.00M | 15.84M | - | 27.52M | 10.54M | 14.80M | - | 16.60M | 14.50M | 13.18M | 12.59M | 15.79M | 14.88M | 17.79M | 20.58M | 28.77M | 36.83M | 49.85M | 45.39M | 44.78M | 49.54M | 40.16M | - | 52.68M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 50.04M | 270.60M | 385.69M | 638.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | 5.20M | 26.07M | 33.30M | 47.48M |
| Gross Profit | - | - | - | - | - | - | - | - | 44.84M | 244.53M | 352.39M | 591.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | 221.34M | 427.44M | 604.83M | 760.25M |
| Operating Income | -5.67M | -9.20M | -27.54M | -27.16M | -32.85M | -67.25M | -99.14M | - | -176.50M | -182.91M | -252.44M | -169.24M |
| EBITDA | - | - | - | - | - | - | - | - | -175.40M | -224.99M | -272.60M | -168.08M |
| Interest Expense | - | - | - | - | - | - | - | - | 7.33M | 6.45M | 6.57M | 6.56M |
| Pretax Income | - | - | - | - | - | - | - | - | -187.13M | -238.28M | -287.13M | -183.70M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 960.00K | 85.00K | -530.00K |
| Net Income | -6.00M | -12.21M | -27.20M | -28.94M | -30.97M | -68.35M | -102.90M | - | -187.13M | -239.24M | -287.22M | -183.17M |
| Diluted EPS | - | - | - | - | - | - | -2.77 | - | -4.60 | -5.27 | -5.99 | -3.68 |
| R&D Expense | 4.28M | 6.78M | 21.20M | 19.96M | 23.50M | 53.65M | 70.24M | 58.06M | 57.95M | 97.94M | 187.08M | 183.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 49.08M | 38.21M | 35.56M | 15.38M | 220.55M | 186.13M | - | 331.48M | 588.24M | 568.50M | 689.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | 245.64M | 504.26M | 485.06M | 588.99M |
| Cash & Equivalents | - | - | - | - | - | - | 219.97M | 183.88M | - | 200.84M | 386.19M | 315.35M | 322.93M |
| Inventory | - | - | - | - | - | - | - | - | - | 4.32M | 15.13M | 15.73M | 27.94M |
| Receivables | - | - | - | - | - | - | - | - | - | 37.70M | 94.82M | 142.00M | 224.46M |
| Total Liabilities | - | - | 2.63M | 16.64M | 18.84M | 14.44M | 41.83M | 72.34M | - | 221.92M | 397.26M | 511.48M | 601.51M |
| Current Liabilities | - | - | 2.63M | 7.17M | 12.18M | 10.82M | 24.49M | 23.44M | - | 96.56M | 138.85M | 230.10M | 378.84M |
| Long Term Debt | - | - | - | 9.47M | 6.66M | 3.62M | 17.33M | 48.32M | - | 94.26M | 178.07M | 180.71M | 117.75M |
| Total Debt | - | - | - | - | - | - | - | - | - | 94.68M | 186.37M | 192.96M | 218.11M |
| Total Equity | -2.03M | -3.20M | 46.44M | 21.57M | 16.72M | 937.92K | 178.72M | 113.79M | - | 109.56M | 190.98M | 57.02M | 88.30M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 43.50M | 47.35M | 48.67M | 50.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.60M | -7.44M | -21.28M | -26.47M | -30.05M | -46.38M | -78.46M | - | -116.51M | -145.08M | -128.41M | -93.41M |
| Investing Cash Flow | - | -20.20K | -104.56K | -9.90K | -32.70K | -16.12K | -45.89K | - | -53.70M | -582.00K | -270.00K | -480.00K |
| Financing Cash Flow | 5.13M | 52.88M | 9.97M | 23.88M | 10.03M | 252.39M | 42.41M | - | 284.58M | 331.01M | 57.84M | 101.47M |
| Capital Expenditure | - | -20.20K | -104.56K | -9.90K | -32.70K | -16.12K | -45.89K | - | -702.00K | -582.00K | -270.00K | -480.00K |
| Free Cash Flow | - | -7.46M | -21.39M | -26.48M | -30.09M | -46.39M | -78.50M | - | -117.21M | -145.66M | -128.68M | -93.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 114.37M | 185.35M | -70.84M | 7.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 89.6% | 90.4% | 91.4% | 92.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | -352.7% | -67.6% | -65.5% | -26.5% |
| Net Margin % | - | - | - | - | - | - | - | - | -374.0% | -88.4% | -74.5% | -28.7% |
| ROE % | 187.4% | -26.3% | -126.1% | -173.1% | -3,301.5% | -38.2% | -90.4% | - | -170.8% | -125.3% | -503.8% | -207.5% |
| ROCE % | - | -19.8% | -88.7% | -116.2% | -720.7% | -34.3% | -60.9% | - | -75.1% | -40.7% | -74.6% | -54.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.60% | 3.91M | $953.27M |
| 2 | Vanguard Portfolio Management LLC | 4.00% | 2.06M | $501.42M |
| 3 | Vanguard Capital Management LLC | 3.77% | 1.94M | $472.08M |
| 4 | FMR, LLC | 3.05% | 1.57M | $381.76M |
| 5 | Price (T.Rowe) Associates Inc | 2.56% | 1.32M | $320.87M |
| 6 | Invesco Ltd. | 2.52% | 1.30M | $316.15M |
| 7 | Geode Capital Management, LLC | 2.26% | 1.16M | $283.33M |
| 8 | Wellington Management Group, LLP | 2.23% | 1.15M | $279.03M |
| 9 | Deep Track Capital, Lp | 2.14% | 1.10M | $267.99M |
| 10 | State Street Corporation | 1.92% | 986.81K | $240.41M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AXSM
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial res…
3 Under-the-Radar Stocks to Buy and Hold
Sometimes, little-known stocks are worth buying.
Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value
Axsome Therapeutics stock has delivered very strong 5 year returns, yet the current valuation checks point to a picture that looks closer to fairly priced than clearly cheap or expensive. Axsome Therapeutics has returned about 338.5% over t…
How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials
Axsome Therapeutics recently announced that it has dosed the first patients in its FOCUS-2 and FOCUS-3 Phase 3 trials, evaluating solriamfetol in children and adolescents with ADHD through randomized, double-blind, placebo-controlled studie…
Axsome Therapeutics (AXSM) Following FOCUS 2 Dosing Is The ADHD Upside Already Priced In
Axsome Therapeutics (AXSM) has kicked off its latest catalyst with the first patient dosed in FOCUS-2, a Phase 3 trial of solriamfetol in children with ADHD, expanding its late stage CNS pipeline. See our latest analysis for Axsome Therapeu…
Dow Jones Futures: Nasdaq Eyes Key Levels Amid Iran News; Nvidia, Valero, Dell, SpaceX In Focus
Tech futures rose overnight after Nvidia, Dell and other AI stocks bounced and SpaceX hit a new low. Oil prices kept rising on Iran news.
AXSM — Frequently Asked Questions
What is the current share price of Axsome Therapeutics, Inc. (AXSM)?
As of 2026-07-14 21:23 PDT, Axsome Therapeutics, Inc. (AXSM) trades at $235.26 on NasdaqGM. Its 52-week range is $100.39 to $255.17.
What is the market capitalisation of AXSM?
Axsome Therapeutics, Inc. (AXSM) has a market capitalisation of $12.11B on NasdaqGM.
What is the P/E ratio of AXSM?
AXSM trades at a trailing price-to-earnings (P/E) ratio of -63.07. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 240.27.
Is AXSM a good stock to buy?
This page provides a data-driven analysis of Axsome Therapeutics, Inc. (AXSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.